Peptide Injection Sites: A Research Reference Guide

Administration route is one of the most consequential variables in peptide research. The choice of injection site affects absorption kinetics, local tissue response, and how consistently researchers can deliver a known quantity of compound. This guide summarizes what the preclinical and pharmacological literature describes regarding subcutaneous and intramuscular administration for the peptide classes commonly studied in laboratory settings. All information is for research purposes only.

Subcutaneous vs. Intramuscular: Which Route for Which Peptide?

Most small research peptides such as BPC-157, TB-500, and ipamorelin are most commonly studied via subcutaneous (SubQ) injection. This route deposits the compound into the fat layer just beneath the skin, where a slower, more sustained absorption profile is established. The subcutaneous route is also technically simpler, requires shorter needles (typically 27-31 gauge, 0.5 inch), and presents a lower risk of intravascular injection.

Intramuscular (IM) injection delivers compound directly into muscle tissue, producing a faster but shorter absorption curve. IM administration appears more frequently in research designs for IGF-1 LR3 and some growth hormone-releasing peptide studies, where proximity to target muscle tissue may be relevant to the experimental model. However, IM injection requires longer needles and more precise technique to avoid nerves and blood vessels.

Table values reflect research-reported administration parameters, not dosing recommendations. Figures are for laboratory reference only.

Common Subcutaneous Injection Sites in Research Models

In rodent models, subcutaneous injections are typically administered in the dorsal scruff (loose skin at the back of the neck). In larger mammalian models and in the published human pilot studies that inform peptide research frameworks, commonly described SubQ sites include:

• Abdomen: The area around the navel is among the most cited sites. Fat depth is generally consistent, and the tissue is accessible. Most published CJC-1295 and ipamorelin research notes abdominal SubQ delivery.
• Lateral thigh: Outer thigh offers predictable fat depth and is used when abdominal sites are being rested in rotation protocols.
• Lateral upper arm: The tricep area provides a usable SubQ depot, though fat depth varies more with body composition.
• Gluteal region: Less practical for self-administration in research subject contexts; used more for IM administration when that route is specified.

Rotation Protocols Described in the Literature

Studies examining peptide administration over multi-week or multi-month windows generally describe systematic rotation to minimize local tissue effects. A simple grid approach divides each anatomical area (e.g., abdomen) into quadrants and cycles through them over consecutive administrations. Some published protocols for BPC-157 and TB-500 research rotate on a two-week cycle across three or four defined zones before returning to the starting site. See the BPC-157 protocol and TB-500 protocol pages for cycle-specific notes.

Longer-acting peptides such as CJC-1295 with DAC, which may be administered once or twice per week, require less frequent rotation than daily-dosing compounds. The lower injection frequency reduces cumulative site stress considerably.

Intranasal Administration

A subset of research peptides are studied via intranasal delivery, which deposits compound on the olfactory and respiratory mucosa. This route is particularly relevant for neuropeptides, because nasal mucosa provides a pathway that bypasses the blood-brain barrier to a partial degree. DSIP (delta sleep-inducing peptide) has been studied both subcutaneously and intranasally. Selank and Semax are almost exclusively studied via intranasal delivery in the Russian literature, using diluted aqueous preparations delivered in small volumes per nostril. Our DSIP dosage reference covers the intranasal figures reported in that research.

Reconstitution and Volume Considerations

Injection volume affects local tolerance. In SubQ research, smaller volumes (0.1-0.5 mL per injection) are better tolerated at a single site than larger boluses. Proper reconstitution of lyophilized peptide vials with bacteriostatic water is a prerequisite for producing solutions of a known concentration and therefore a defined injection volume. If the concentration is unknown or incorrectly calculated, the intended dose cannot be delivered accurately regardless of technique. Use the peptide calculator to confirm concentration and volume before administration in any research context. A full walkthrough of reconstitution steps is available in the peptide reconstitution guide.

Sterility and Storage at the Administration Stage

Aseptic technique is non-negotiable in any administration-focused research design. Alcohol swabbing of the vial septum before each draw, use of a new needle for each injection, and proper storage of reconstituted solution at 2-8 degrees Celsius all affect both compound stability and the validity of the research outcome. Degraded or contaminated peptide introduces confounding variables that invalidate results. Sourcing from vendors with documented sterility testing is the first line of quality control; the supplier reference lists vendors that provide third-party analysis.

Site-Specific Notes for Key Peptides

For researchers working with specific compounds, the protocol pages provide administration notes alongside dosage figures:

• BPC-157 protocol: SubQ or oral depending on the study model; SubQ preferred for systemic effect studies.
• TB-500 protocol: SubQ or IM both appear in the literature; SubQ is most common in human subject research frameworks.
• Ipamorelin protocol: SubQ injection, typically timed relative to fasting state in GH secretagogue studies.
• IGF-1 LR3 protocol: IM injection near target muscle tissue is common in satellite cell and muscle hypertrophy research designs.